Trials / Completed
CompletedNCT00266695
Treatment for Completers of the Study B7A-MC-MBCM
Open-Label Treatment for Patients Completing Study B7A-MC-MBCM
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Chromaderm, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment. Patients must be off study drug for 6 to 18 months from completion of B7A-MC-MBCM before beginning B7A-MC-MBDV. Additional data will be gathered to determine the long-term safety and effect of ruboxistaurin on vision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruboxistaurin | 32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years. |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2005-12-19
- Last updated
- 2016-10-06
- Results posted
- 2016-01-28
Locations
29 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00266695. Inclusion in this directory is not an endorsement.